1396841-05-6 Usage
General Description
Methyl (S)-2-(2-chlorophenyl)-2-(4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl)acetate is a chemical compound that is commonly used in pharmaceutical research and development. methyl (S)-2-(2-chlorophenyl)-2-(4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl)acetate is a derivative of thieno[2,3-c]pyridine, which is known for its potential in the treatment of a variety of medical conditions. Methyl (S)-2-(2-chlorophenyl)-2-(4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl)acetate is often used as a building block in the synthesis of new drug candidates, particularly those targeting neurological and psychiatric disorders. methyl (S)-2-(2-chlorophenyl)-2-(4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl)acetate is also of interest in the study of chemical biology and medicinal chemistry, as it may have potential applications in the development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1396841-05-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,6,8,4 and 1 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1396841-05:
(9*1)+(8*3)+(7*9)+(6*6)+(5*8)+(4*4)+(3*1)+(2*0)+(1*5)=196
196 % 10 = 6
So 1396841-05-6 is a valid CAS Registry Number.
1396841-05-6Relevant articles and documents
Synthesis and characterization of impurity B of S-(+)-clopidogrel bisulfate: An antiplatelet
Reddy, K. Tatendra,Kumar, K. Suneel,Omprakash,Dubey
, p. 1387 - 1396 (2013/05/22)
S-(+)-Clopidogrel bisulfate [(S-(+)-methyl 2-(2-chlorophenyl)-2-(6, 7-dihydrothieno[3, 2-c]pyridin-5(4H)-yl)acetate bisulfate)] is a platelet aggregation inhibitor drug. S-(+)-Clopidogrel bisulfate is prepared by different synthetic approaches in the literature. In almost all the approaches the major impurities known in the literature (A, B, and C) are also listed in the U.S. pharmacopoeia. The control of these pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. In this article, a description of these impurities and their origins in the S-(+)-clopidogrel bisulfate process are presented along with the preparation of impurity B.
